Matthew Sims
Overview
Explore the profile of Matthew Sims including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fabregas-Tejeda A, Sims M
Hist Philos Life Sci
. 2025 Feb;
47(1):10.
PMID: 39913055
The research programme 'basal cognition' adopts an evolutionary perspective for studying biological cognition. This entails investigating possible cognitive processes in 'simple'-often non-neuronal-organisms as a means to discover conserved mechanisms and...
2.
Bhavani S, Spicer A, Sinha P, Malik A, Lopez-Espina C, Schmalz L, et al.
Intensive Care Med
. 2024 Oct;
50(12):2094-2104.
PMID: 39382693
Purpose: Sepsis is a heterogeneous syndrome. Identification of sepsis subphenotypes with distinct immune profiles could lead to targeted therapies. This study investigates the immune profiles of patients with sepsis following...
3.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Aug;
13(10):2209-2210.
PMID: 39212853
No abstract available.
4.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Jun;
13(10):2105-2121.
PMID: 38941068
Introduction: Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics...
5.
Lee Y, Liu L, Yuan L, Risk M, Heinrich K, Witteveen-Lane M, et al.
medRxiv
. 2023 Nov;
PMID: 37961376
Background: Some studies conducted before the Delta and Omicron variant-dominant periods have indicated that influenza vaccination provided protection against COVID-19 infection or hospitalization, but these results were limited by small...
6.
Berenson C, Lashner B, Korman L, Hohmann E, Deshpande A, Louie T, et al.
Clin Infect Dis
. 2023 Aug;
77(11):1504-1510.
PMID: 37539715
Background: Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind,...
7.
Kaye K, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C, Daikos G, et al.
NEJM Evid
. 2023 Aug;
2(1).
PMID: 37538951
Background: Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant (XDR) , XDR , and carbapenem-resistant Enterobacterales (CRE) are associated with high mortality rates, and therapeutic options remain limited. This...
8.
Abbas M, Farhat N, Hammoud Z, Dickey C, Shuayto A, Chen N, et al.
J Intensive Care Med
. 2023 Feb;
38(6):511-518.
PMID: 36775970
Severe acute respiratory syndrome coronavirus 2 (SARS-CoaV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic. In randomized clinical trials, patients who were treated with the anti-spike monoclonal antibody bamlanivimab...
9.
Cohen S, Louie T, Sims M, Wang E, Memisoglu A, McGovern B, et al.
JAMA
. 2022 Oct;
328(20):2062-2064.
PMID: 36260754
No abstract available.
10.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Infection (rCDI)
Khanna S, Sims M, Louie T, Fischer M, LaPlante K, Allegretti J, et al.
Antibiotics (Basel)
. 2022 Sep;
11(9).
PMID: 36140013
Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20−25% of patients...